Markets:

Overview

News

Currencies

International

Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

28.55 +1.61 (+5.99%)

Delayed Quote Updated: 2:42 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Zenas BioPharma, Inc. - Common Stock

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. ↗

June 21, 2026

This clinical-stage biotech focused on immunology therapies reported a notable insider buy amid a year of strong stock performance.

Via The Motley Fool

Topics Regulatory Compliance

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗

March 21, 2026

This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.

Via The Motley Fool

Why Is ZBIO Stock Falling Pre-Market Today? ↗

January 06, 2026

Via Stocktwits

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗

October 31, 2025

Via MarketBeat

1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗

October 28, 2025

Via MarketBeat

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 27, 2025

Via Benzinga

Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948 ↗

October 16, 2025

Via The Motley Fool

Topics Regulatory Compliance

Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug ↗

October 08, 2025

Zenas BioPharma secures global rights to orelabrutinib in multiple sclerosis, expands autoimmune pipeline, and raises $120 million in private placement.

Via Benzinga

Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 01, 2025

Via Benzinga

Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

April 01, 2025

Via Benzinga

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress ↗

March 20, 2025

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.

Via Benzinga

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 22, 2025

Via Benzinga

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

December 16, 2024

Via Benzinga

Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

December 11, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 25, 2024

Via Benzinga

StandardAero Surges In Market Debut ↗

October 06, 2024

Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at...

Via Talk Markets

Topics Initial Public Offering

Week In Review: Zenas Raises $259 Million In IPO ↗

September 28, 2024

It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259...

Via Talk Markets

Topics Initial Public Offering

Trio Of Biotech IPOs Climb In Debut ↗

September 15, 2024

A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public...

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.